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  37 
Abstract 38 
Objectives: Altered linezolid pharmacokinetics in obese individuals has been hypothesized in previous 39 
studies. However, specific dosing recommendations for this population are still lacking. The main goal 40 
of this study was to evaluate pharmacokinetic/pharmacodynamic (PKPD) target attainment of a 600 41 
mg intravenous q12h linezolid dose against MRSA in obese patients with pneumonia.  42 
Methods: Fifteen obese pneumonia patients with a confirmed or suspected MRSA involvement 43 
treated with 600 mg of intravenous linezolid q12h were studied for three days. Population 44 
pharmacokinetic modelling was used to characterize the pharmacokinetic variability and to screen for 45 
influential patient characteristics. Monte Carlo simulations were carried out to investigate the PTA and 46 
time to target attainment for linezolid dosing against MRSA in the obese population.   47 
Results: A two-compartmental model with linear elimination adequately described the data. Body 48 
weight and age both have a significant effect on linezolid clearance. Simulations demonstrate that the 49 
probability of attaining PKPD targets is low. Moreover, probability of target attainment (PTA) decreases 50 
with weight, and increases with age. Standard linezolid dosing in obese pneumonia patients with MRSA 51 
(MICs of 1–4 mg/L) leads to unacceptably low (near zero to 60%) PTA for patients less than 65 years 52 
old.  53 
Conclusions: Standard linezolid dosing is likely to provide insufficient target attainment against MRSA 54 
in obese patients. Body weight and especially age are important characteristics to be taken into 55 











The increasing worldwide prevalence of obesity is one of the major burdens on healthcare.1, 2 Obese 67 
individuals not only have a higher morbidity compared to their non-obese counterparts,3, 4 successful 68 
treatment may also be hampered by uncertainty in terms of correct drug dosing. Drug dosing in 69 
obese patients is generally considered off-label as in most cases obese patients are not included in 70 
clinical trials during drug development. As such, the dosing regimens in the label might not be 71 
suitable for treating obese patients. Pathophysiology changes in obese patients can have a significant 72 
influence on drug distribution and elimination, thereby altering a drug’s pharmacokinetics 73 
characteristics.4-6 Consequently, overdosing or underdosing is likely to occur in this specific 74 
population.3 This issue may especially be of significant clinical relevance for drug treatments in which 75 
the effect of the drug is difficult to monitor, for example for antibiotic treatments.  76 
MRSA is a Gram-positive micro-organism that is resistant to most antibiotics.7, 8 The increasing 77 
prevalence of MRSA is becoming a major therapeutic challenge in hospitals worldwide.9, 10 Linezolid , 78 
the first antibacterial agent of the group of the oxazolidinones antibiotics, is used to treat 79 
pneumonia, skin and soft tissue infections caused by Gram-positive bacteria including MRSA.11, 12 As a 80 
moderately lipophilic drug (logP of 0.9), linezolid is mainly metabolized in the liver and only 30% of 81 
the drug is renally eliminated.13 Linezolid has a relatively low (31%) plasma protein binding, and its 82 
steady-state volume of distribution is 40 – 50 L, which approximates total body water.14  For the case 83 
of linezolid treatment, the pharmacokinetic/pharmacodynamic (PK/PD) indices strongly correlated 84 
with clinical eradication of the invading pathogen, are the time the linezolid concentration remains 85 
above the MIC (T>MIC) and the ratio of AUC/MIC over 24 h.9, 14 86 
The current recommended dose of linezolid is 600 mg q12 h via intravenous (i.v.) or oral 87 
administration. At the moment, there are no specific dosing recommendations for obese patients. 88 
Nevertheless, alterations of linezolid pharmacokinetics have been described in obese patients.10, 15-20 89 
In two case reports and a small cohort study (n=7), linezolid serum concentrations in obese patients 90 
were found to be lower than in normal-weight patients.10, 15, 17 Furthermore, Bhalodi et al.18 showed a 91 
positive association between the volume of distribution and body weight for moderately and 92 
morbidly (otherwise healthy) obese adults. This finding was confirmed in population pharmacokinetic 93 
studies of linezolid in normal-weight and obese patients.16, 20 However, no information is available on 94 
the pharmacokinetics of linezolid in obese patients and the efficacy of a 600 mg q12h dosing for the 95 
treatment against MRSA in this specific population.  96 
Therefore, the goal of this study was to determine PKPD target attainment as a surrogate measure 97 
for linezolid efficacy in obese pneumonia patients with MRSA involvement. With this study we 98 
aimed: i) to describe the pharmacokinetic variability of linezolid concentrations in a cohort of obese 99 
patients using population pharmacokinetic modelling, ii) to evaluate the influence of patient 100 
characteristics on the probability of target attainment against MRSA and  iii) to evaluate the time 101 
course of target attainment within patients throughout therapy.  102 
Patients and methods  103 
Ethics 104 
The research was conducted in accordance with the Declaration of Helsinki and national and 105 
institutional standards. The study protocol was reviewed and approved by the local institutional 106 
review boards of the participating centers (ClinicalTrials.gov Identifier: NCT01805284). Written 107 
informed consent was obtained for all patients prior to their enrollment in the study.  108 
Study design and patients 109 
This multi-center and open-label study of linezolid pharmacokinetics was conducted at University 110 
Hospital of Larissa, University Hospital of Ioannina, and University Hospital Heraklion, Greece from 111 
2014 to 2016. Patients were enrolled if they met all of the following inclusion criteria: (i) age 18 years 112 
or more; (ii) obese (BMI > 35 kg/m2); (iii) confirmed or clinically suspected hospital-, healthcare-, or 113 
community-acquired pneumonia; (iv) a confirmed infection for MRSA involvement; (v) admitted to 114 
ICU; (vi) decision to start treatment with linezolid therapy. Exclusion criteria were: (i) absence of an 115 
arterial line for blood sampling, (ii) anuria, (iii) pregnancy, (iv) need for renal replacement therapy 116 
and (v) prior administration of more than one dose of intravenous linezolid.  117 
Drug administration and sample collection  118 
During the study participants received six 600 mg doses of i.v. linezolid q12 h. All doses were 119 
administered via a 30 min infusion. Blood samples were collected before every drug administration, 120 
and at 0.5 (end of the infusion), 0.75, 1, 1.25, 1.5, 2, 4, 6, 8, 10, 12 h after the start of the sixth dose. 121 
Blood samples were centrifuged within 30 minutes (4°C, 10 min, 1500xg) and transferred into a 122 
polystyrene labeled tube and frozen at -20°C until shipment. Samples were pooled and transported 123 
on dry ice from the study centers to the Laboratory of Medical Biochemistry and Clinical Analysis, 124 
Ghent University where samples were then stored at -80 °C until analysis. 125 
Protein binding and sample measurement 126 
Protein binding was determined for each patient using four plasma samples taken from three 127 
different days. Briefly, plasma samples were first incubated in a portable mini CO2 incubator (N-128 
BIOTECK, Korea) for 30 min (37°C, 10% CO2). After the incubation, 400 µL of plasma was transferred 129 
into an Amicon® Ultra-0.5 filter (0.5 mL, 30 KDa; Merck Millipore, Darmstadt, Germany) and 130 
centrifuged at 3200 g for 10 min at 37 °C to obtain the ultrafiltrate (Cunbound). A separate plasma 131 
sample was incubated as a quality control to determine the total drug concentration (Ctotal). Protein 132 
binding (%) was calculated as 100 × (1 – Cunbound/Ctotal). The mean value of protein binding was 133 
reported for each patient.  134 
Total and unbound linezolid concentrations were measured using a previously developed liquid 135 
chromatography-tandem mass spectrometry validated for the simultaneous quantification of β-136 
lactam antibiotics and oxazolidinone antibiotic linezolid in human plasma.21  The method bias and 137 
precisions for linezolid were less than 9.7% and 11.2%, respectively. The lower limit of quantification 138 
of linezolid in plasma was 0.05 mg/L. 139 
Population pharmacokinetic modelling 140 
Software. Nonlinear mixed-effects modelling was performed in NONMEM® (version 7.3, Icon 141 
Development Solutions, Ellicott City, MD, USA) employing first-order conditional estimation (FOCE) 142 
with interaction, assisted by Perl-Speaks-NONMEM (version 4.60, Uppsala University, Uppsala, 143 
Sweden) through the Pirana workbench (version 2.9.6, Pirana Software). Data processing, 144 
simulations and plotting were carried out in R® 3.4.1 (R Foundation for Statistical Computing, Vienna, 145 
Austria).  146 
Model development. The population model was developed in a stepwise manner with a log-147 
transform-both-sides (LTBS) approach used. Different structural models such as one- and two- 148 
compartmental models with linear and/or non-linear eliminations were tested. Inter-individual 149 
variability (IIV) and inter-occasion variability (IOV) were assumed to follow a log-normal distribution. 150 
The additive error model in the log domain was used throughout the entire process. All PK 151 
parameters were allometrically scaled to a total body weight of 70 kg. This means that the allometric 152 
exponent was fixed at 1.0 for all volume terms and 0.75 for all clearance terms. Covariates were 153 
screened by applying the stepwise forward addition (p<0.05) and backward elimination (p<0.01) 154 
procedure. Covariates tested were: age, sex, severity of sepsis episode (sepsis, severe sepsis, and 155 
septic shock), creatinine clearance estimated by the Cockroft & Gault formula,22 serum albumin, 156 
alanine transaminase, aspartate aminotransferase, and total bilirubin.  157 
Model selection and evaluation. Model comparison was guided by changes in the objective function 158 
value (OFV) between nested models (with a decrease > 3.84 points being statistically significant for 159 
the inclusion of a single parameter), the Akaike information criterion (AIC) between non-nested 160 
models, the condition number (CN), the relative standard error (RSE) of the parameter estimates, 161 
and goodness-of-fit plots.23, 24 The final PK model was evaluated using: (i) the visual predictive check 162 
(VPC) method (1000 simulations),25 (ii) the normalized prediction distribution errors (NPDE),26 and 163 
(iii) the sampling importance resampling (SIR) procedure for the assessment of parameter 164 
uncertainty.27  165 
Prediction of PK/PD target attainment   166 
The PK/PD index of AUC/MIC > 100 and T>MIC of 100% were used for the evaluation of linezolid 167 
treatment efficacy in study patients.28 In order to evaluate the observed target attainment, the 168 
AUC/MIC and T>MIC values were derived from the post hoc PK parameter estimates for each patient 169 
at time intervals between 0 – 24 h, 24 – 48 h, and 48 – 72 h. The MIC of 4 mg/L was chosen because 170 
this concentration is considered as the linezolid-susceptible breakpoint for most S. aureus isolates 171 
including MRSA (from EUCAST website).29 The probability of target attainment was stratified 172 
according to patient characteristics to evaluate potential associations.   173 
Monte Carlo simulation  174 
The final population PK model was used to conduct Monte Carlo simulations with the dosage 175 
regimen of 600 mg i.v. linezolid q12 h for 3 days. The simulation was performed from 0 to 72 h at two 176 
scenarios: (i) 10000 virtual subjects with a fixed age of 60 years (median observed age in this cohort), 177 
and weight levels sampled randomly from a uniform distribution ranging from 50 to 160 kg; (ii) 10000 178 
virtual subjects with a fixed weight of 125 kg (median observed weight), and age values sampled 179 
randomly from a uniform distribution ranging from 30 to 85 years. The probability of target 180 
attainment (PTA)  against the MIC values (1, 2, and 4 mg/L) within linezolid susceptible breakpoint for 181 
MRSA was calculated at the periods of 0 – 24 h, 24 – 48 h, and 48 – 72 h. According to the MIC 182 
distribution of MRSA for linezolid from EUCAST MIC database 183 
(https://mic.eucast.org/Eucast2/regShow.jsp?Id=13366, last accessed August 30th, 2018), the MICs of 184 
1, 2 , and 4 mg/L represent 1.40%, 54.08%, 44.46%, and in total 99.88% of the distribution. The 185 
cumulative fraction of response (CFR) that accounted for the selected MIC distribution was 186 
computed to further qualify linezolid target attainment in patient populations. In all scenarios, the 187 
following PKPD targets were used: 100 % T>MIC, AUC/MIC>100 and a combination of AUC/MIC>100 188 
and 100 % T>MIC.  189 
Results 190 
Patient characteristics 191 
A total of 9 males and 6 females were included in the study. All patients completed the study. 192 
Recruitment of MRSA-positive, obese patients with pneumonia proved to be problematic. Moreover, 193 
linezolid is frequently used empirically in patients with an overt risk profile for MRSA involvement. 194 
Therefore, we decided to also include patients who were MRSA-negative. We consider this as a 195 
minor protocol violation as we expect no influence on the pharmacokinetic profiling. Consequently, 196 
only two of the included patients were MRSA-positive. A summary of the demographic and clinical 197 
characteristics for the included patients are shown in Table 1.   198 
 199 
Population pharmacokinetic analysis 200 
A two-compartment model with linear elimination adequately described the linezolid concentrations. 201 
An additional IIV term on the residual error variance significantly improved the model fit (drop in OFV 202 
of 37.1) and was therefore retained in the model. This term allows for the residual error to vary 203 
between individuals. Implementation of IOV on PK parameters was tested and for clearance was 204 
found to be statistically significant (drop in OFV of 31.1). Besides the weight effect, we found a linear 205 
age effect on clearance (drop in OFV of 9.9). The final linezolid population PK model is summarized 206 
with equations 1–4: 207 



















)                                                                                              (4) 211 
where CL is linezolid clearance, θage is age effect parameter on CL, Vc is linezolid central volume of 212 
distribution, Q is intercompartmental linezolid clearance, Vp is linezolid peripheral volume of 213 
distribution, θ is population estimate, η is IIV, and κ is IOV. 214 
The parameter estimates and associated standard errors for the final model are shown in Table 2. 215 
The goodness-of-fit plot shown in Figure 1 suggests an overall good fit of the model to the data. The 216 
VPC and the histogram of the NPDEs used as to internally validate the final model are provided as 217 
Supplementary data (Figures S1 and S2). 218 
Prediction of PK/PD target attainment  219 
The predicted AUC/MIC and T>MIC values for each patient at day 1, day 2, and day 3, together with 220 
the covariates of interest are listed in Table 3. In addition to the PKPD indices which were derived 221 
from total concentrations, as recommended in literature,11, 28 the unbound fractions of linezolid are 222 
reported for future reference. At an MIC of 4 mg/L, the fraction of patients attaining an 223 
AUC/MIC>100 increases from 0% on day 1 to 13.3% on days 2 and 3. For the T>MIC of 100%, 26.7% 224 
patients (4/15 patients) reached this target on days 1 and 2. This fraction increased to 33.3% (5/15 225 
patients) on day 3.  226 
Only 13.3% of the patients achieved an AUC/MIC>100 and T>MIC of 100% at steady state. Figure S3 227 
of the supplementary data shows AUC/MIC and T>MIC as a function of the patient characteristics 228 
(i.e. weight and age). From this Figure one can see that AUC/MIC values are positively associated 229 
with age, and negatively associated with body weight.  230 
Monte Carlo simulation 231 
The indices T>MIC, AUC/MIC, and a combination of them were all used frequently in previous 232 
linezolid PKPD studies.4,11 It is reported that for linezolid treatment T>MIC and AUC/MIC were highly 233 
correlated and performed similarly related to clinical outcomes.28 Herein, we mainly focused on the 234 
100% T>MIC target as linezolid is considered a time-dependent killing antibiotic especially against S. 235 
aureus.30 The estimated PTAs and CFRs of 100% T>MIC versus weight and age for the three days of 236 
treatment against different MIC values are shown in Figure 2. The estimated PTAs and CFRs versus 237 
weight and age for the AUC/MIC>100 and combined 100%T>MIC and AUC/MIC>100 targets are 238 
supplied in Figures S4 and S5 of the online supplement for reference.  239 
Our PKPD simulations show that patients with large body weight are at a higher risk of not attaining 240 
the PKPD targets. The CFR for patients weighting 85 kg (the lowest observed weight) is 27.3% at 241 
steady state, and the probability drops to 19.2% for patients weighting 160 kg (the highest observed 242 
weight). When target of AUC/MIC>100 is considered, the weight effect on CFR is much more 243 
significant with a 3.5-fold drops in probability observed. On the contrary, from the bottom panel in 244 
Figure 2 it can be seen that the PKPD target attainment is considerably higher in elderly patients. For 245 
patients 30 years old (the lowest observed age), the CFR is extremely low (2.8%), even at steady 246 
state. The target attainment rate rises to 98.7% for 85-year old patients (the highest observed age). 247 
In all studied scenarios, the PTAs are quite low (< 60%) even at the lowest MIC (1 mg/L) except for 248 
the elderly patients (≥ 65 years), regardless of the PKPD indices used. 249 
Discussion  250 
This study aimed to address the question whether a standard 600 mg q12h dosing regimen is 251 
efficacious for the treatment of MRSA in obese patients with pneumonia using linezolid PKPD target 252 
attainment as a surrogate marker. Our study showed that body weight and age are significantly 253 
affecting linezolid pharmacokinetics. Moreover, these patient characteristics have a substantial 254 
influence on the probability of attaining PKPD indices associated with therapeutic success.    255 
The pharmacokinetic behavior of linezolid has been studied before in healthy volunteers and obese 256 
patients. Abe et al.20 and Minichmayr et al.31 showed, in elderly patients and critically ill patients 257 
respectively, that linezolid clearance decreases with age. On the contrary, in a healthy volunteer 258 
study, Sisson et al.32 showed no influence of age on clearance. Our results confirm that for obese 259 
patients linezolid clearance decreases with age from a value of 15.54 L/h for 30-year old patients to 260 
1.35 L/h in 85 year-old patients. By incorporating a size correction into our model based on 261 
allometric theory,33 we ascertained that our model aligns with earlier work where it was shown that 262 
linezolid PKs are influenced by a patient’s body weight.16, 19, 20, 31 Although creatinine clearance was 263 
previously shown to influence linezolid clearance,19, 31 it was not retained as a covariate in our model. 264 
This was most likely because the majority of patients in our study had mild to moderate renal failure 265 
and renal clearance only accounts for 30 % of total drug elimination.  266 
It was previously shown that PTA against pathogens with an MIC of 4 mg/L is low in normal weight 267 
and obese patients. Cojutti et al.19 found a PTA of below 10% in overweight and obese patients 268 
following a 600mg q12h dosing regimen of linezolid. At the same time, Minichmayr et al.31 and Yang 269 
et al.34 found a PTA of near zero in normal weight healthy volunteers. Our findings in obese patients 270 
are in line with these previous findings in both normal weight and obese patients. Through PKPD 271 
simulations we showed that, depending on the PKPD index, probability of target attainment of 272 
typical obese patients (weighting 125 kg and 60 years old) with an MIC of 4 mg/L is zero on day 1 and 273 
between 1.03% and 11.88% on day 3 of treatment. 274 
In contrast to these findings, Cojutti et al.19 reported a high cumulative fraction of response  (>80%) 275 
against MRSA strains in overweight and obese patients. However, in their analysis Cojutti et al. used 276 
an MIC distribution (0.12 – 2 mg/L, MIC90 of 1 mg/L) of Staphylococci from a local surveillance 277 
program. In line with these findings, Puzniak et al.35 found a high weight-independent clinical success 278 
rate (86.2%) against complicated skin and skin structure infections and nosocomial pneumonia 279 
caused by MRSA. However, similar to the work by Cojutti et al., most patients (+/-90%) in the study 280 
by Puzniak et al. had an MIC less or equal to 1 mg/L. The MRSA MIC distribution for linezolid from the 281 
EUCAST MIC database, as used in this study, is significantly different (range from 1 – 4 mg/L, with the 282 
MIC90 being 4 mg/L) leading to substantially lower CFRs. We feel that, based on the high prevalence 283 
of MRSA with MICs of 2 and 4 mg/L (in total 98.48% of MIC distribution), the approach by Cojutti et 284 
al.19 might falsely over-estimate the CFR against MRSA. 285 
When considering our results, the reader should appreciate that our study has some limitations. 286 
First, although plasma PK was frequently sampled, the population PK modelling and covariate 287 
screening was based on data from only 15 obese patients. This could have prevented the inclusion of 288 
more subtle covariate relationships in our model and might have impacted the accuracy of the 289 
estimation of inter-individual variability terms. Second, due to difficulties in including patients with a 290 
documented MRSA infection we were not able to study the influence of MRSA infection on the PKs of 291 
linezolid and the ensuing effect on PTA. Third, we simulated target attainment for the first three days 292 
of treatment whilst it was previously shown that the average PKPD target attainment (e.g. across the 293 
first 7 days of therapy) was correlated to clinical cure 28. As such, target attainment reported here 294 
might falsely under- or over-estimate the probability for clinical cure. Finally, simulated PTAs for 295 
normal-weight subjects relied on extrapolation from our study population via allometric scaling. 296 
Although our extrapolated PTAs are in good agreement with previous reports in normal-weight 297 
subjects, our data did not allow us to formally test allometric scaling and the reported results in 298 
normal-weight subjects should be interpreted taking into account this uncertainty.   299 
In conclusion, through population PK modelling and PKPD simulations we demonstrated that a 300 
600mg q12h dosing regimen is unlikely to be efficacious against MRSA infections in obese patients 301 
with pneumonia. We feel that our results, in combination with earlier reports on low target 302 
attainment against MRSA in normal-weight and obese patients, provide sufficient scrutiny to advice 303 
against standard linezolid dosing for the treatment of MRSA in obese patients.   304 
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Table 1. Baseline characteristics of study patients (n=15) 412 
Characteristic n (%) or median (IQRa) 
Age (years) 64.5 (56.2 – 71.0) 
Male/female 9 (60)/6 (40) 
MRSA microbiology: positive/negative 2 (13.3) /13 (86.7) 
Body weight (kg) 125.0 (112.5 – 133.0) 
Height (cm) 169.0 (160.0 – 174.5) 
BMI (kg/m2) 40.0 (37.8 – 49.4) 
Obese (BMI>35 kg/m²) / morbidly obese patients 
(BMI>40 kg/m²) 
5 (33.3)/10 (66.7) 
Sepsis episode: sepsis/severe sepsis/septic shock 5 (33.3)/7 (46.7)/3 (20) 
Serum creatinine (mg/dL) 1.42 (1.16 – 1.64) 
Creatinine clearance (Cockroft & Gault, mL/min)  80.8 (66.7 – 107.6) 
Serum albumin (g/dL) 3 (2.5 – 3.3) 
Alanine transaminase (IU/L) 35 (22.2 – 40.5) 
Aspartate aminotransferase (IU/L) 45 (22.5 – 53.5) 
Total bilirubin (mg/dL) 0.61 (0.46 – 1.09) 
Trough total concentration at 72 h (mg/L) 0.95 (0.33 – 2.75) 
Unbound fraction (%) 83.1 (78.9 – 87.3) 

















Table 2. Population parameter estimates of the final pharmacokinetic model and the results of the 430 
sampling importance resampling (SIR) approach 431 
Parameter 
Final pharmacokinetic model   SIR results 
Estimate (RSE%) [Shrinkage%]   Median 95% CI 
Fixed effects 
θCL (L/h/70 kg) 7.8 (12.1)  8.1 6.2 – 10.1 
θage (1/year) -0.0331 (4.6)  -0.0331 -0.0367 – -0.0300 
Vc (L/70 kg) 14.3 (5.3)  14.3 12.8 – 15.8 
Q (L/h/70 kg) 65.1 (12.8)  67.8 53.2 – 85.1 
Vp (L/70 kg) 23.8 (6.5)  24.2 21.3 – 27.0 
      
Inter-individual variability (IIV) 
CL (CV%) 66.9 (36.2) [0.1]  72.8 47.6 – 111.1 
Vc (CV%) 43.5 (33.8) [1.1]  46.2 35.9 – 77.3 
   ωCL,Vc 0.23 (34.4)  0.26 0.12 – 0.47 
IIV on residual error magnitude 96.5 (28.3)  98.9 60.8 – 153.6       
Inter-occasional variability (IOV) 
CL (CV%) 16.1 (47.5) [3-46]  16.7 11.9 – 22.1       
Residual variability 
Proportional  errora (%) 15.9 (7) [0.6]   15.8 13.6 – 18.0 
RSE, relative standard error; CI, confidence intervals; θCL, typical clearance; θage, age effect parameter 432 
on clearance; Vc, volume of distribution of the central compartment; Q, inter-compartmental 433 
clearance between central and peripheral compartment; Vp, volume of distribution of the peripheral 434 
compartment; ωCL,Vc, covariance between the variances of CL and Vc.                               435 
CV (%) is calculated according to: CV (%) = �exp (ω2)− 1 × 100%. ω2: the variance estimate in 436 
the log-domain. 437 
a An additive error model in the log-transformed domain was used to characterize the residual 438 











Table 3. Calculated PKPD indices in study patients together with the selected patient characteristics 450 













1 11.6 11.9 13.5 3.9 4.0 4.7 48.3 115 79.1 
2 23.6 24.2 22.9 9.5 9.8 9.1 58.1 129 69.1 
3 16.5 15.8 16.9 5.8 5.5 6.1 54.4 118 89.0 
4 70.9 126.5 161.8 24.0 24.0 24.0 84.7 87 86.2 
5 31.3 36.2 35.2 15.2 17.3 16.6 45.8 151 83.1 
6 23.8 28.7 37.8 10.0 13.5 19.5 60.6 135 87.5 
7 6.8 7.9 8.0 1.5 1.8 1.9 64.5 125 70.7 
8 32.8 43.5 43.1 15.1 21.9 20.7 72.2 105 85.4 
9 17.8 15.7 14.8 6.5 5.6 5.1 59.5 110 93.5 
10 48.9 69.3 76.2 24.0 24.0 24.0 75.7 118 80.2 
11 48.6 64.2 67.4 24.0 24.0 24.0 67.7 131 71.9 
12 13.4 18.1 17.8 3.6 6.3 6.3 69.9 160 78.7 
13 33.0 42.5 52.0 16.6 22.5 24.0 72.2 135 91.1 
14 9.7 10.4 10.7 2.9 3.2 3.4 32.1 130 82.3 




















Figure 1. Goodness-of-fit plots of the final linezolid population pharmacokinetics model. Top left 470 
panel: Observed concentrations versus population predictions of linezolid in plasma; Top right panel: 471 
Observed concentrations versus individual predictions of linezolid in plasma; Bottom left panel: 472 
conditional weighted residuals (CWRES) versus population predicted linezolid concentrations; 473 




Figure 2. The probability of target attainment (PTA) and cumulative fraction of response (CFR) versus 478 
weight (top panels) and age (bottom panels) against different MIC values on three consecutive days 479 
for 600 mg every 12h linezolid treatment. PTA was determined using T>MIC of 100% at MICs of 1 480 
(dotted line), 2 (dotdash line), and 4 (longdash line) mg/L. CFR was shown as the solid line. The 481 
simulated population in the upper rows were at a fixed age of 60 years and in the bottom rows were 482 
at a fixed weight of 125 kg.  483 
